Publications
362
Citations
3,942
Est. group size
~63
Recurring co-author estimate
Active years
26
Publishing since 2001
Dukagjin Blakaj's research focuses on radiation oncology, particularly the treatment of head and neck cancers including HPV-related oropharyngeal cancer. Recent work centers on large clinical trials examining chemotherapy combinations (cisplatin vs. cetuximab) used alongside radiation therapy, patient quality of life outcomes, and genetic markers (such as the KRAS-variant) that may predict treatment response. This work is largely conducted through multi-institutional cooperative group trials (NRG/RTOG) rather than single-lab studies.
Publication output has grown substantially over the last decade, rising from single digits in 2017 to a steady pace of roughly 40 publications per year in recent years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- HPV-positive cancers at uncommon sites: a narrative review
Oncology Reviews · 2026
- Quality of Life in Patients With p16+ Oropharyngeal Cancer Receiving Accelerated Radiation Therapy With Either Cisplatin or Cetuximab in the NRG/RTOG 1016 Randomized Controlled Trial
International Journal of Radiation Oncology*Biology*Physics · 2026
- Supplementary Table 13 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
- Supplementary Figure 5 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
- Supplementary Table 3 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
- Figure 1 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
- Table 1 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
- Supplementary Table 10 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
- Supplementary Figure 1 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
- Supplementary Table 11 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
- Supplementary Figure 4 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
- Supplementary Table 8 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
- Figure 2 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
- Supplementary Table 2 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
- Table 3 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
- International Journal of Radiation Oncology*Biology*Physics×81
- Journal of Clinical Oncology×22
- Cancers×13
- Radiotherapy and Oncology×10
- Annals of Oncology×10
- J.C. Grecula
Medicine · The Ohio State University
- Sujith Baliga
Medicine · The Ohio State University
- Emile Gogineni
Medicine · The Ohio State University
- Brett Klamer
Medicine · The Ohio State University
- Carol R. Bradford
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile